Skip to main content

Advertisement

SpringerLink
Log in

Case report: successful treatment of membranous lupus nephritis with belimumab in an African female immigrant

  • Case Based Review
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

We describe the case of a 26-year-old African female who was treated successfully with belimumab in a case of severe membranous lupus nephritis and retinal vasculitis, resistant to first line therapy. She presented initially with chronic dacryoadenitis and screening showed nephrotic-range proteinuria. Biopsy of the kidney confirmed the diagnosis of membranous lupus nephritis. Clinical features (joint pain, dacryoadenitis, retinal vasculitis and lupus nephritis) in combination with serology (positive anti-double-stranded DNA (ds-DNA) antibodies, hypocomplementemia) confirmed the diagnosis of systemic lupus erythematosus (SLE). Treatment was immediately initiated with glucocorticosteroids (GCS), mycophenolate mofetil (MMF) and hydroxychloroquine sulphate (Plaquenil®). Tacrolimus was associated but no effect was observed with the proteinuria remaining in the nephrotic range and secondary effects of the glucocorticosteroids becoming a real concern. The patient was started on add-on belimumab with quasi-immediate effect on the proteinuria, making it possible to decrease the dosage of the other immunosuppressants and gradually stop them, even the GCS. The patient is currently in complete remission after 3 years of treatment with belimumab. We were able to stop immunosuppressive treatment but will keep her on antimalarial treatment as the most recent guidelines in treatment of SLE recommend.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Appel GB, Contreras G, Dooley MA et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. JASN 20:1103–1112

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Navarra SV, Guzman RM, Gallacher AE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377(9767):721–731

    Article  CAS  PubMed  Google Scholar 

  3. Manzi S, Sánchez-Guerrero J, Merrill J (2012) Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 71:1833–1838

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Hahn B, McMahon M, Wilkinson A et al (2012) American College of Rheumatology guidelines for screening, case definition, treatment and management of lupus nephritis. Arthritis Care Res 64(6):797–808

    Article  Google Scholar 

  5. Hahn BH (2013) Belimumab for systemic lupus erythematosus. N Engl J Med 368:1528–1535

    Article  CAS  PubMed  Google Scholar 

  6. Fließer EE, Korsten P, Koziolek MJ, Niewold TB, Patschan D, Müller GA, Patschan SA (2013) Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman. Lupus 22:1523–1525

    Article  PubMed  Google Scholar 

  7. van Vollenhoven RF, Petri MA, Cervera R et al (2012) Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 71:1343–1349

    Article  PubMed  PubMed Central  Google Scholar 

  8. Dooley MA, Houssiau F, Aranow C (2013) Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 22(1):63–72

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. HIV Translational Research Unit, Department of Internal Medicine, Faculty of Medicine and Health Sciences, Ghent University (Campus UZGent Hospital), De Pintelaan 185, De Pintepark, 9000, Ghent, Belgium

    Marie-Angélique De Scheerder

  2. Department of Nephrology, AZ Glorieux, Ronse, Belgium

    O. Boey, E. Mahieu, J. Vanuytsel & Anne-Marie Bogaert

  3. Department of Nephrology, AZ Sint-Elisabeth, Zottegem, Belgium

    Anne-Marie Bogaert

Authors
  1. Marie-Angélique De Scheerder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Boey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Mahieu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Vanuytsel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anne-Marie Bogaert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marie-Angélique De Scheerder.

Ethics declarations

Disclosures

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

De Scheerder, MA., Boey, O., Mahieu, E. et al. Case report: successful treatment of membranous lupus nephritis with belimumab in an African female immigrant. Clin Rheumatol 35, 1649–1653 (2016). https://doi.org/10.1007/s10067-015-3153-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-015-3153-1

Keywords

Search

Navigation